Home / Pharmaceuticals / Pharmaceutical Intermediates Market By Product (Bulk Drug Intermediates, Chemical Intermediates, Custom Intermediates), By End User (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organization, Research Laboratories) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Pharmaceutical Intermediates Market By Product (Bulk Drug Intermediates, Chemical Intermediates, Custom Intermediates), By End User (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organization, Research Laboratories) - Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Published: Jul 2019 | Report Code: 59749-07-19

Industry Outlook

The pharmaceutical intermediates market is set to reach from US$ 25,965.0 Mn in 2018 to US$ 36,890.6 Mn by 2027 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2019 to 2027. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.

Market Synopsis

Pharmaceutical Intermediates Market

Get a sample copy for more information

"Significant rise in drug formulation research & development (FR&D) activities to boost the bulk intermediates market growth"

Bulk drug intermediates are reigning the product segment for pharmaceutical intermediates market. The key driver associated with its market growth is the significant rise in the drug formulation research & development (FR&D).  They are used as raw material in manufacturing of bulk drugs or as a secondary product generated during the synthesis of active pharmaceutical ingredient (API) having potential to be used in various drug formulation. Custom intermediates are gaining huge traction on account of increased drug development and research activities and burgeoning requirement of novel medicines to treat orphan diseases.

Pharmaceutical Intermediates Market

Get a sample copy for more information

"Rising prevalence of life threatening diseases and stringent regulatory norms imposed by healthcare agencies worldwide propel the pharmaceutical & biotechnology companies worldwide"

Pharmaceutical & biotechnology companies are spearheading the end user segment for pharmaceutical intermediates market. The key drivers associated with its dominating market growth are rising prevalence of life threatening diseases and stringent regulatory norms pertaining to cGMP and cGLP guidelines for drug manufacturing imposed by healthcare agencies worldwide. Research laboratories have shown impressive growth in the last 2 decades on account of increasing demand for pharmaceutical intermediates in developing novel medicines for treating rare and autoimmune diseases. Contract manufacturing organization will be highlighting rampant growth during the forecast period on account of increasing demand for generic medicines due to patent expiration of blockbuster drugs in the near future and significant rise in drug manufacturing outsourcing activities to penetrate untapped market worldwide.

Pharmaceutical Intermediates Market

Get a sample copy for more information

"Presence of well developed healthcare infrastructure and rising public health awareness together drive the market growth in North America"

North America presently holds 35.8% market growth and is the largest regional segment for pharmaceutical intermediates market. The drivers responsible for its positive market growth are presence of well developed healthcare infrastructure and rising public health awareness. Europe is placed second I the regional segment representing 30.4% market share on account of significant rise in patient population seeking medical intervention for life threatening diseases and supportive regulatory environment provided by European Medical Agency (EMA) for pharmaceutical intermediates market. Asia Pacific is accountable for 20.2% market share owing to proactive government policies resulting in flourishing drug manufacturing activities and serves as a lucrative market opportunity for western giants to enter into strategic collaboration and agreement with local players owing to the flourishing generic drug market in Asia Pacific region.

Pharmaceutical Intermediates Market

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market segmentation comprises of by product, end user and geography. 

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 By Product (2017–2027; US$ Mn)
 • Bulk Drug Intermediates
 • Chemical Intermediates
 • Custom Intermediates

 By End User (2017–2027; US$ Mn)
 • Pharmaceutical and Biotechnology Companies
 • Contract Manufacturing Organization
 • Research Laboratories

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Companies producing pharmaceutical intermediates are BASF SE, Bristol Myers Squibb Company, Cambrex Corporation, Chiracon GmbH, Codexis, Inc., Dishman Group, Dextra Laboratories, Ltd., Lonza, Midas Pharma GmbH and Vertellus Holdings LLC.

Key questions answered in this report

  • Which pharmaceutical companies are competing in the pharmaceutical intermediates market?
  • What are the latest DRO’s pertaining to pharmaceutical intermediates market?
  • Why is bulk intermediates the leading product segment?
  • What will be the market performance of contract manufacturing organization?
  • What will be the market size and CAGR of Asia Pacific, Latin America and Middle East and Africa during the forecast period?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PI Market Portraiture
2.2. Global PI Market, by Product, 2018 (US$ Mn)
2.3. Global PI Market, by End User, 2018 (US$ Mn)
2.4. Global PI Market, by Geography, 2018 (US$ Mn)

Chapter 3. Pharmaceutical Intermediates (PI) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global PI Market, by Key Players, 2018

Chapter 4. Global Pharmaceutical Intermediates (PI) Market, by Product
4.1. Overview
4.2. Bulk Drug Intermediates
4.3. Chemical Intermediates
4.4. Custom Intermediates

Chapter 5. Global Pharmaceutcials Intermediates (PI) Market, by End User
5.1. Pharmaceutical & Biotechnology Companies
5.2. Contract Manufacturing Organization
5.3. Research Laboratories

Chapter 6. Global Pharmaceutical Intermediates (PI) Market, by Geography
6.1. Overview
6.2. North America PI Market Analysis, 2017– 2027
6.2.1. North America PI Market, by Product, 2017 – 2027 (US$ Mn)
6.2.2. North America PI Market, by End User, 2017 – 2027 (US$ Mn)
6.2.3. North America PI Market, by Country, 2017 – 2027 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe PI Market Analysis, 2017 – 2027
6.3.1. Europe PI Market, by Product, 2017– 2027 (US$ Mn)
6.3.2. Europe PI Market, by End User, 2017 – 2027 (US$ Mn)
6.3.3. Europe PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific PI Market Analysis, 2017 – 2027
6.4.1. Asia Pacific PI Market, by Product, 2017 – 2027 (US$ Mn)
6.4.2. Asia Pacific PI Market, by End User, 2017– 2027 (US$ Mn)
6.4.3. Asia Pacific PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America PI Market Analysis, 2017 – 2027
6.5.1. Latin America PI Market, by Product, 2017 – 2027 (US$ Mn)
6.5.2. Latin America PI Market, by End User, 2017 – 2027 (US$ Mn)
6.5.3. Latin America PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa PI Market Analysis, 2017 – 2027
6.6.1. MEA PI Market, by Product, 2017 – 2027 (US$ Mn)
6.6.2. MEA PI Market, by End User, 2017 – 2027 (US$ Mn)
6.6.3. MEA PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. BASF SE
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Bristol Myers Squibb Company
7.3. Cambrex Corporation
7.4. Chiracon GmbH
7.5. Codexis, Inc.
7.6. Dishman Group
7.7. Dextra Laboratories, Ltd.
7.8. Lonza
7.9. Midas Pharma GmbH
7.10. Vertellus Holdings LLC

* Here we are using PI as a short form of Pharmaceutcials Intermediates

FIG. 1 Pharmaceutical Intermediates (PI) Market: Research Methodology
FIG. 2 PI: Market Segmentation
FIG. 3 Global PI Market, by Product, 2018 (US$ Mn)
FIG. 4 Global PI Market, by End User, 2018 (US$ Mn)
FIG. 5 Global PI Market, by Geography, 2018 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global PI Market, by Key Players, 2018
FIG. 8 Global Bulk Drug PI Market, 2017 – 2027 (US$ Mn)
FIG. 9 Global Chemical PI Market, 2017– 2027 (US$ Mn)
FIG. 10 Global Custom PI Market, 2017 – 2027 (US$ Mn)
FIG. 11 Global Pharmaceutical & Biotechnology Companies Market for PI, 2017 – 2027 (US$ Mn)
FIG. 12 Global Contract Manufacturing Organization Market for PI, 2017 – 2027 (US$ Mn)
FIG. 13 Global Research Laboratories Market for PI, 2017 – 2027 (US$ Mn)
FIG. 14 U.S. PI Market, 2017 – 2027 (US$ Mn)
FIG. 15 Canada PI Market, 2017 – 2027 (US$ Mn)
FIG. 16 U.K. PI Market, 2017 – 2027 (US$ Mn)
FIG. 17 Germany PI Market, 2017– 2027 (US$ Mn)
FIG. 18 Rest of Europe PI Market, 2017 – 2027 (US$ Mn)
FIG. 19 China PI Market, 2017 – 2027 (US$ Mn)
FIG. 20 Japan PI Market, 2017 – 2027 (US$ Mn)
FIG. 21 Rest of Asia Pacific PI Market, 2017 – 2027 (US$ Mn)
FIG. 22 Brazil PI Market, 2017 – 2027 (US$ Mn)
FIG. 23 Mexico PI Market, 2017 – 2027 (US$ Mn)
FIG. 24 Rest of Latin America PI Market, 2017 – 2027 (US$ Mn)
FIG. 25 GCC PI Market, 2017 – 2027 (US$ Mn)
FIG. 26 Rest of MEA PI Market, 2017 – 2027 (US$ Mn)

TABLE 1 Global Pharmaceutical Intermediates (PI) Market Portraiture
TABLE 2 Global PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 3 Global PI Market , by End User, 2017 – 2027 (US$ Mn)
TABLE 4 Global PI Market, by Geography, 2017 – 2027(US$ Mn)
TABLE 5 North America PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 6 North America PI Market, by End User, 2017 – 2027 (US$ Mn)
TABLE 7 North America PI Market, by Country, 2017 – 2027 (US$ Mn)
TABLE 8 Europe PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 9 Europe PI Market, by End User, 2017 – 2027(US$ Mn)
TABLE 10 Europe PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 11 Asia Pacific PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 12 Asia Pacific PI Market, by End User, 2017 – 2027 (US$ Mn)
TABLE 13 Asia Pacific PI Market, by Country/Region, 2017– 2027 (US$ Mn)
TABLE 14 Latin America PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 15 Latin America PI Market, by End User, 2017 – 2027 (US$ Mn)
TABLE 16 Latin America PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 17 Middle East and Africa PI Market, by Product, 2017 – 2027 (US$ Mn)
TABLE 18 Middle East and Africa PI Market, by End User, 2017 – 2027 (US$ Mn)
TABLE 19 Middle East and Africa PI Market, by Country/Region, 2017 – 2027 (US$ Mn)
TABLE 20 BASF SE: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Bristol Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Cambrex Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Chiracon GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Codexis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Dishman Group: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Dextra Laboratories, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Lonza: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Midas Pharma GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Vertellus Holdings LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients